Sponsor: NRG
Sponsor Study ID: NRG-GU015
Study Title: NRG-GU015: The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER)
CTO #: 104267
NCT Number: NCT07097142
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Bladder
Study Objectives: Demonstrate non-inferiority of ultra-hypofractionated (SBRT) compared to hypofractionated RT with a 10% non-inferiority margin (from 50% to 40%) in the rate of bladder-intact event-free survival (BI-EFS) at 3 years (corresponding to a hazard ratio <1.32)